Source: https://www.fr.com/megan-chacon/
Timestamp: 2019-04-26 02:11:08+00:00

Document:
Megan Chacon is a Principal in the Southern California office of Fish & Richardson. Her practice emphasizes complex patent litigation across a wide range of technologies. Ms. Chacon has extensive experience in the life sciences and pharmaceutical fields, including Hatch-Waxman litigation. She has worked on matters involving a wide variety of pharmaceutical compounds, formulations, and treatment methods for conditions such as schizophrenia, bipolar depression, pain management, hepatitis C virus, oral testosterone therapy, and osteoporosis. Ms. Chacon also has experience with biotechnology, chemicals, medical devices, and consumer products.
Ms. Chacon’s experience covers all aspects of pre-litigation due diligence and litigation, including case assessment, domestic and international document collection and production, managing fact and expert discovery teams and strategy, depositions, dispositive motions, Markman hearings, settlement strategy, and pre-trial and trial work. While Ms. Chacon focuses her practice in the United States District Courts and has appears in many across the country, she also has experience with the U.S. International Trade Commission.
Prior to joining the firm, Ms. Chacon practiced as a patent litigator at a leading intellectual property law firm in New York focusing on Hatch-Waxman litigation. Ms. Chacon also served as a Student Judicial Extern to The Honorable Clark Waddoups, United States District Court, District of Utah (2009).
“Mayo at Five: Are Traditional Method of Treatment Claims in Danger Under Section 101?,” co-authored with Geoff Biegler and Dalia Kothari, Fish Litigation Blog (October 9, 2017).
“Mayo at Five: Eligibility of Diagnostic Method Claims,” co-authored with Geoff Biegler and Dalia Kothari, Fish Litigation Blog (September 6, 2017).
“Diagnostics Patent Eligibility: A Turning Point Approaches,” co-authored with Jenny Shmuel, Life Sciences Intellectual Property Review (February 16, 2016).
Life Sciences Patent Eligibility “101”: Mayo at Five, co-authored with Geoff Biegler and Dalia Kothari.
“Patentable Subject Matter in the Life Sciences,” University of San Diego School of Law Intellectual Property Law Conference (March 22, 2019).
“Biosimilar and Hatch-Waxman Litigation,” San Diego Office CLE Event (January 24, 2018).
“Fishbowl Session,” facilitator, Benchmark Litigation Women In Business Law Forum Los Angeles (September 28, 2017).
Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharma Ltd. et al. (D. NJ): Representing Plaintiffs in Hatch-Waxman litigation over schizophrenia and bipolar depression medication LATUDA®.
Yeiser Research & Development LLC v. Teknor Apex Co. (S.D. Cal.): Representing Defendant in trade secret and breach of contract litigation over Teknor Apex’s Zero G garden hose.
iCeutica Inc. et al v Lupin, Ltd., et al. (D. Md.): Representing Plaintiffs in Hatch-Waxman litigation over pain medication VIVLODEX®.
Gilead Sciences, Inc. v. AbbVie (D. Del.): Represented Plaintiff in litigation over its hepatitis C treatment HARVONI®.
Allergan Sales, LLC v. Aurobindo Pharma Ltd. et al. (EDTX): Represented Plaintiff in Hatch-Waxman litigation over ocular pain drug ACULAR® LS.
Clarus Therapeutics, Inc. v. Lipocine Inc. (D. Del.): Represented Defendant in litigation related to Defendant’s oral testosterone therapy formulation.
iCeutica Inc. et al v Lupin, Ltd., et al. (D. Del): Represented Plaintiffs in Hatch-Waxman litigation over pain medication ZORVOLEX®.
Warner Chilcott Co., LLC v. Teva Pharmaceuticals USA, Inc. (D. NJ): Represented Plaintiff in Hatch-Waxman litigation over osteoporosis treatment ATELVIA® (prior to joining Fish & Richardson).
Authors: Megan A. Chacon, Jenny Shmuel, Ph.D.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.